P. McAndrew

发表

Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome

R. Elashoff, A. Giuliano, C. Hudis, 2008 .

Fat metabolism and cancer.

P. McAndrew, Philomena F. McAndrew, 1986, The Surgical clinics of North America.

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

T. Doman, M. Morris, J. Durack, 2020, Clinical Cancer Research.

Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.

Robert M Elashoff, Alan Kristal, Bette Caan, 2007, Journal of the National Cancer Institute.

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).

M. Morris, H. McArthur, C. Klebanoff, 2019, Journal of Clinical Oncology.

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.

A. Giuliano, A. Bardia, H. McArthur, 2022, Journal of Clinical Oncology.

Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).

H. McArthur, W. Urba, M. Martel, 2019, Journal of Clinical Oncology.

A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

H. McArthur, Brady Bernard, W. Urba, 2023, NPJ breast cancer.

Abstract PD10-01: The PEARL trial: Pre-operative pembrolizumab with radiation therapy in early stage triple negative breast cancer

A. Giuliano, H. McArthur, V. Bossuyt, 2022, Cancer Research.

Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.

S. Karlan, Z. Zumsteg, F. Amersi, 2024, Cancer cell.